Opportunity
Simpler Grants.gov #RFA-DE-27-002
NIH Presolicitation for Resource Centers Supporting Tissue Engineering and Regenerative Medicine
Buyer
National Institute of Dental and Craniofacial Research (NIDCR)
Posted
October 04, 2023
Respond By
January 25, 2026
Identifier
RFA-DE-27-002
NAICS
541715
The National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), is preparing to issue a Notice of Funding Opportunity for Resource Centers supporting tissue engineering and regenerative medicine (TE/RM). - Government Buyer: - National Institute of Dental and Craniofacial Research (NIDCR), NIH - Scope of Work: - Formation and operation of extramural Resource Centers (RCs) - RCs will provide expertise in clinical, scientific, industrial, regulatory, and commercialization areas - Support for Interdisciplinary Translational Projects (ITPs) focused on validation, manufacturing, and preclinical testing - Products/Services Requested: - Guidance and support for TE/RM products and strategies, including therapeutics (e.g., adult stem cell-based treatments), sensors, and diagnostics - Aim to develop products with regulatory approvals and clinical protocols for first-in-human studies - Unique Requirements: - RCs must help select and guide projects addressing tissue damage from congenital defects, traumatic injury, or chronic disease - Focus on readiness for clinical trials and regulatory compliance - No specific OEMs, vendors, products, or part numbers are named in this presolicitation - Applications are not yet being solicited; this is an advance notice to allow preparation
Description
The National Institute of Dental and Craniofacial Research (NIDCR), along with other NIH Institutes and Centers, plans to fund extramural Resource Centers (RCs) to support tissue engineering and regenerative medicine (TE/RM) strategies and products. These RCs will provide expertise to select and guide Interdisciplinary Translational Projects (ITPs) focused on therapeutics, sensors, and diagnostics. The funding will support validation, manufacturing, and preclinical testing of products aimed at detecting or treating tissue damage from congenital defects, injury, or chronic disease. The goal is to develop TE/RM products ready for first-in-human studies with regulatory approvals and clinical protocols in place. Applications are not currently being solicited; this notice is to allow potential applicants time to prepare.